Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Theravance Biopharma excels in Q2 with strong sales growth

Theravance Biopharma delivered strong financial performance in Q2 2024, driven by robust sales of YUPELRI and Trelegy.
While facing challenges such as ongoing losses and R&D expenses, the company remains focused on innovation and operational efficiency.
With a solid cash position, key patent grants, and growth opportunities in new markets, Theravance is poised for future growth and value creation.
Investors can look forward to potential milestones and market expansion initiatives as Theravance continues to execute its strategic vision.

Theravance Biopharma reports strong Q3 performance and strategic growth plans

Theravance Biopharma (TBPH) delivered strong financial performance in Q3 2024, driven by robust sales growth of YUPELRI and TRELEGY, supported by strategic cost management.
The company's focus on unlocking shareholder value through a Strategic Review Committee and commitment to long-term innovation position it for sustainable growth.
While facing challenges in meeting sales milestones and managing expenses, Theravance has opportunities to leverage its product performance and financial stability for future success.
With a solid cash position and prudent financial planning, Theravance is poised to navigate challenges and capitalize on growth opportunities in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) Initiate CYPRESS study in Q1 2023 and submit orphan drug designation in early 2023 Complete PIFR-2 study for YUPELRI® in 2H 2023 Execute $250 million return of capital program, of which ~50% has been completed as of 12/31/2022 Achieve Non-GAAP 1 profitability by 2H 2023 DUBLIN , Jan. 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced its 2022 Accomplishments and 2023 Key Targets. "Last year was a transformative year for Theravance Biopharma and demonstrates the power of a team that leans into the Company's values and core purpose: delivering medicines that make a difference.

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?

DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the "Shares"), which expired at midnight, New York City time, at the end of the day on November 17, 2022. Based on the final count by Computershare Trust Company, N.A.

Theravance Biopharma, Inc. Announces Final Results of Tender Offer

DUBLIN , Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the preliminary results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the "Shares"), which expired at midnight, New York City time, at the end of the day on November 17, 2022. Based on the preliminary count by Computershare Trust Company, N.A.

Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer

Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.

Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Douglas Tsao – H.C. Wainwright Joseph Stringer – Needham Brian Skorney – Baird David Risinger – SVB Securities Operator Ladies and gentlemen, good afternoon.

Theravance Biopharma, Inc. (TBPH) Q3 2022 Earnings Call Transcript

Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates

Royalty Pharma

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35% share) 1 Presented ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 33rd International Symposium on the Autonomic Nervous System Continued to build the Company's intellectual property portfolio with patent covering YUPELRI until 2039 Closed transaction to sell TRELEGY ELLIPTA royalty interests to Royalty Pharma for approximately $1.1 billion in upfront cash, up to $250 million of potential milestones, outer year royalties and an investment in ampreloxetine Initiated a $250 million capital return program; purchased GSK's entire holdings at $9.75 per share; launched a Dutch auction tender offer for up to $95 million of its ordinary shares Eliminated debt and ended third quarter with $487 million of cash DUBLIN , Nov. 7, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter of 2022. "This quarter is a milestone in the Company's transformation and demonstr ates the power of a team of people who are focused and stay true to the Company's purpose, delivering medicines that make a difference.

Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

Totality of Evidence from the Phase 3 Clinical Program Demonstrates Ampreloxetine was Effective in Treating Symptoms and Improving Activities of Daily Living in MSA Patients with Neurogenic Orthostatic Hypotension Safety Profile of Ampreloxetine was Similar to that of Placebo DUBLIN , Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS). Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

DUBLIN , Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022

DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society, taking place November 2-5, 2022, in Maui, Hawaii. The data include three consecutive platform presentations on Wednesday, November 2, 2022, starting at 11:15 AM Maui, HI (5:15 PM ET / 2:15 PM PT / 9:15 PM GMT): Biaggioni I, et al.

Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System

DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a "modified Dutch auction" tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the "Shares").

Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares

Theravance Biopharma Inc. TBPH, +0.20% said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.61% . The company will purchase GSK's entire holdings of about 9.6 million shares at $9.75 a share with the closing expected Tuesday.

Theravance Biopharma plans $250 million capital return program

The Company has agreed to purchase GSK's entire holdings at $9.75 per share The Company plans to launch a Dutch auction tender offer in the near term to purchase approximately $95 million of its ordinary shares The Company plans to enter into an Open Market Share Repurchase Plan subsequent to the tender offer utilizing the additional approximately $ 60 million DUBLIN , Sept. 19, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) announced today that its Board of Directors has authorized a $250 million capital return program consisting of the following three elements: Theravance Biopharma has executed a definitive agreement with GSK to purchase all of GSK's equity stake in Theravance Biopharma, constituting approximately 9.6 million shares at $9.75 per share, with a closing date of September 20, 2022.

Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program

DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be webcast: Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13 at 11:10 am ET (8:10 am PT/4:10 pm IST) H.C.

Theravance Biopharma to Present at Upcoming Investor Conferences

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2022 Conference Call.

Theravance Biopharma, Inc.'s (TBPH) CEO Rick Winningham on Q2 2022 Results - Earnings Call Transcript

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA filing with one additional Phase 3 clinical study in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) Closed transaction to sell TRELEGY ELLIPTA royalty interests to Royalty Pharma for approximately $1.1 billion in upfront cash with over $1.5 billion in total potential value Launched tender offer for outstanding 3.25% Convertible Senior Notes  DUBLIN , Aug. 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2022. "The Company has continued to execute on its strategy and, since the first quarter, we have accomplished several transformative goals.

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

DUBLIN , July 26, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a tender offer (the "Offer") to purchase any and all of its outstanding 3.25% Convertible Senior Notes due 2023 (the "Convertible Notes"). As of July 26, 2022, there were $230,000,000 aggregate principal amount of the Convertible Notes outstanding.

Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva?

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

Shares of Theravance Biopharma Inc. TBPH, -0.80% were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's GSK, -1.25% Trelegy Ellipta to Royalty Pharma RPRX, -0.40% for $1.1 billion in cash and up to $450 million in potential milestone payments. Trelegy Ellipta is a treatment for asthma and chronic obstructive pulmonary disease.

Theravance sets up deal to sell rights to asthma drug to Royalty Pharma

Innoviva

Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc's (NYSE: GSK) TRELEGY ELLIPTA to Royalty.

News for Theravance Biopharma Stock (TBPH)